Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma
Christopher G. Wood, … , Thomas Powles, W. Kimryn Rathmell
Christopher G. Wood, … , Thomas Powles, W. Kimryn Rathmell
Published November 19, 2020
Citation Information: JCI Insight. 2020;5(22):e132852. https://doi.org/10.1172/jci.insight.132852.
View: Text | PDF
Clinical Medicine Clinical trials Oncology

Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma

  • Text
  • PDF
Abstract

BACKGROUND Surgery remains the frontline therapy for patients with localized clear cell renal cell carcinoma (ccRCC); however, 20%–40% recur. Angiogenesis inhibitors have improved survival in metastatic patients and may result in responses in the neoadjuvant setting. The impact of these agents on the tumor genetic heterogeneity or the immune milieu is largely unknown. This phase II study was designed to evaluate safety, response, and effect on tumor tissue of neoadjuvant pazopanib.METHODS ccRCC patients with localized disease received pazopanib (800 mg daily; median 8 weeks), followed by nephrectomy. Five tumors were examined for mutations by whole exome sequencing from samples collected before therapy and at nephrectomy. These samples underwent RNA sequencing; 17 samples were available for posttreatment assessment.RESULTS Twenty-one patients were enrolled. The overall response rate was 8 of 21 (38%). No patients with progressive disease. At 1-year, response-free survival and overall survival was 83% and 89%, respectively. The most frequent grade 3 toxicity was hypertension (33%, 7 of 21). Sequencing revealed strong concordance between pre- and posttreatment samples within individual tumors, suggesting tumors harbor stable core profiles. However, a reduction in private mutations followed treatment, suggesting a selective process favoring enrichment of driver mutations.CONCLUSION Neoadjuvant pazopanib is safe and active in ccRCC. Future genomic analyses may enable the segregation of driver and passenger mutations. Furthermore, tumor infiltrating immune cells persist during therapy, suggesting that pazopanib can be combined with immune checkpoint inhibitors without dampening the immune response.FUNDING Support was provided by Novartis and GlaxoSmithKline as part of an investigator-initiated study.

Authors

Christopher G. Wood, James E. Ferguson III, Joel S. Parker, Dominic T. Moore, Jennifer G. Whisenant, Susan J. Maygarden, Eric M. Wallen, William Y. Kim, Mathew I. Milowsky, Kathryn E. Beckermann, Nancy B. Davis, Scott M. Haake, Jose A. Karam, Dante S. Bortone, Benjamin G. Vincent, Thomas Powles, W. Kimryn Rathmell

×

Figure 3

Results of the DNA allelic frequency analysis.

Options: View larger image (or click on image) Download as PowerPoint
Results of the DNA allelic frequency analysis.
(A) Hierarchical cluster ...
(A) Hierarchical cluster analysis of mutations from pre- to posttreatment samples reveals close clustering of corresponding pre- and posttreatment samples. Each tumor is annotated along x axis. MAF, mutant allele frequency. (B) Overall total mutations are decreased in posttreatment tumors. (C) The number of private mutations for each sample was divided by the overall number of mutations between the pairs to yield the fraction of private mutations: a reflection of increasing clonality in the post-treatment tumors. (D) Density plots comparing all mutations with shared mutations only (private mutations excluded) shows that differences between samples are due to private mutations.

Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts